Clinical trial
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin…
NCT00011414 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00011414 |
|---|---|
| Title | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors |
| Official title | Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer |
| Intervention type | Drug |
| Interventions | Tariquidar |
| Enrollment | 29 |
| Start date | Feb 15, 2001 |
| Primary completion | Nov 28, 2007 |
| Completion | Jan 13, 2016 |
| First posted | Feb 19, 2001 |
| Last update posted | Jul 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: